Literature DB >> 12373519

Neuroprotective and neurotoxic roles of levodopa (L-DOPA) in neurodegenerative disorders relating to Parkinson's disease.

R M Kostrzewa1, J P Kostrzewa, R Brus.   

Abstract

Despite its being the most efficacious drug for symptom reversal in Parkinson's disease (PD), there is concern that chronic levodopa (L-DOPA) treatment may be detrimental. In this paper we review the potential for L-DOPA to 1). autoxidize from a catechol to a quinone, and 2). generate other reactive oxygen species (ROS). Overt toxicity and neuroprotective effects of L-DOPA, both in vivo and in vitro, are described in the context of whether L-DOPA may accelerate or delay progression of human Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12373519     DOI: 10.1007/s00726-001-0110-x

Source DB:  PubMed          Journal:  Amino Acids        ISSN: 0939-4451            Impact factor:   3.520


  17 in total

Review 1.  Sources and targets of reactive oxygen species in synaptic plasticity and memory.

Authors:  Kenneth T Kishida; Eric Klann
Journal:  Antioxid Redox Signal       Date:  2007-02       Impact factor: 8.401

2.  Rivastigmine for dementia associated with Parkinson's disease.

Authors:  John Morgan; Kapil D Sethi
Journal:  Curr Neurol Neurosci Rep       Date:  2005-07       Impact factor: 5.081

3.  Acute L: -DOPA effect on hydroxyl radical- and DOPAC-levels in striatal microdialysates of parkinsonian rats.

Authors:  Przemysław Nowak; Rose Anna Kostrzewa; Dariusz Skaba; Richard M Kostrzewa
Journal:  Neurotox Res       Date:  2009-09-04       Impact factor: 3.911

4.  Effects of hydrogen sulfide-releasing L-DOPA derivatives on glial activation: potential for treating Parkinson disease.

Authors:  Moonhee Lee; Valerio Tazzari; Daniela Giustarini; Ranieri Rossi; Anna Sparatore; Piero Del Soldato; Edith McGeer; Patrick L McGeer
Journal:  J Biol Chem       Date:  2010-04-05       Impact factor: 5.157

5.  No increased chromosomal damage in L-DOPA-treated patients with Parkinson's disease: a pilot study.

Authors:  Rajaraman Gnana Oli; Gholamreza Fazeli; Wilfried Kuhn; Susanne Walitza; Manfred Gerlach; Helga Stopper
Journal:  J Neural Transm (Vienna)       Date:  2010-04-18       Impact factor: 3.575

6.  Neuroprotection by pergolide against levodopa-induced cytotoxicity of neural stem cells.

Authors:  Wei-Guo Liu; Yan Chen; Biao Li; Guo-Qiang Lu; Sheng-Di Chen
Journal:  Neurochem Res       Date:  2004-12       Impact factor: 3.996

Review 7.  Dopamine- or L-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease.

Authors:  Masato Asanuma; Ikuko Miyazaki; Norio Ogawa
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

8.  Roflupram exerts neuroprotection via activation of CREB/PGC-1α signalling in experimental models of Parkinson's disease.

Authors:  Jiahong Zhong; Wenli Dong; Yunyun Qin; Jinfeng Xie; Jiao Xiao; Jiangping Xu; Haitao Wang
Journal:  Br J Pharmacol       Date:  2020-02-26       Impact factor: 8.739

9.  Microglial responses to dopamine in a cell culture model of Parkinson's disease.

Authors:  Diego Mastroeni; Andrew Grover; Brian Leonard; Jeffrey N Joyce; Paul D Coleman; Brooke Kozik; Denise L Bellinger; Joseph Rogers
Journal:  Neurobiol Aging       Date:  2008-03-05       Impact factor: 4.673

10.  Impairment of neuronal mitochondrial function by L-DOPA in the absence of oxygen-dependent auto-oxidation and oxidative cell damage.

Authors:  Philipp Hörmann; Sylvie Delcambre; Jasmin Hanke; Robert Geffers; Marcel Leist; Karsten Hiller
Journal:  Cell Death Discov       Date:  2021-06-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.